Investor Presentaiton slide image

Investor Presentaiton

Financial Highlights Income Statement EGP'000 Revenue 30 June 2018 (Unaudited) 865,853 (446,660) 419,193 30 June 2017 (Unaudited) 685,133 (366,867) 318,266 Cost of sales Gross profit Marketing and advertising expenses (41,442) (29,568) Administrative expenses (78,372) (60,154) Other expenses (5,995) Operating profit 293,384 224,243 Finance income (4,301) 18,121 (16,316) 1,805 28,819 Finance cost (18,168) Net finance income/(cost) 10,651 Profit before tax 304,035 226,048 Income tax expense (89,675) (66,048) Profit for the period 214,360 160,000 Profit attributed to: Owners of the Company Non-controlling interest Earnings per share (expressed in EGP): Basic and diluted earnings per share 216,462 155,344 (2,102) 4,656 214,360 160,000 1.44 1.04 Revenues increased 26% to EGP 866 million in 1H2018, driven primarily by improved pricing as the Group capitalised on the inflationary environment it operates within and successfully targeted a larger number of higher-margin walk-in patients. The Group's strong revenue performance came despite the slow period during the holy month of Ramadan. Gross profit increased at a rate faster than revenues, closing at EGP 419 million in 1H2018 or 32% higher y-o-y. Gross profit improved thanks to a higher contribution from higher-margin walk-in patients, a favourable test mix and management's success in controlling costs amidst an inflationary environment. Gross profit margin rose two percentage points to 48% versus 46% recorded in 1H2017. EBITDA grew 29% to EGP 329 million in 1H2018 compared to EGP 255 million in the same period last year. The Group's EBITDA margin improved to 38% compared to 37% in 1H2017. Excluding the Nigerian operation, EBITDA growth would have been 32% in 1H2018 with an EBITDA margin of 40%. 32 INTEGRATED DIAGNOSTICS HOLDINGS
View entire presentation